Plus Therapeutics, Inc.
PSTV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,397 | $1,390 | $1,059 | $1,412 |
| % Growth | 0.5% | 31.3% | -25% | – |
| Cost of Goods Sold | $86 | $86 | $181 | $232 |
| Gross Profit | $1,311 | $1,304 | $878 | $1,180 |
| % Margin | 93.8% | 93.8% | 82.9% | 83.6% |
| R&D Expenses | $2,436 | $1,246 | $1,756 | $2,186 |
| G&A Expenses | $0 | $1,682 | $2,839 | $3,126 |
| SG&A Expenses | $3,357 | $1,682 | $2,839 | $3,126 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$86 | -$181 | -$232 |
| Operating Expenses | $5,793 | $2,842 | $4,414 | $5,080 |
| Operating Income | -$4,482 | -$1,538 | -$3,536 | -$3,900 |
| % Margin | -320.8% | -110.6% | -333.9% | -276.2% |
| Other Income/Exp. Net | $59 | $6,689 | -$13,865 | -$3 |
| Pre-Tax Income | -$4,423 | $5,151 | -$17,401 | -$3,903 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,423 | $5,151 | -$17,401 | -$3,903 |
| % Margin | -316.6% | 370.6% | -1,643.2% | -276.4% |
| EPS | -0.04 | 0.025 | -1.19 | -0.5 |
| % Growth | -262.6% | 102.1% | -138% | – |
| EPS Diluted | -0.04 | -0.007 | -1.19 | -0.66 |
| Weighted Avg Shares Out | 107,429 | 48,389 | 14,567 | 7,865 |
| Weighted Avg Shares Out Dil | 1,074,290 | 209,155 | 14,567 | 5,896 |
| Supplemental Information | – | – | – | – |
| Interest Income | $59 | $27 | $1 | $54 |
| Interest Expense | $0 | $0 | $3,759 | $57 |
| Depreciation & Amortization | $86 | $121 | $181 | $232 |
| EBITDA | -$4,337 | $5,272 | -$13,461 | -$3,614 |
| % Margin | -310.5% | 379.3% | -1,271.1% | -255.9% |